Abraham et al., 2013 - Google Patents
Premenopausal bone health: osteoporosis in premenopausal womenAbraham et al., 2013
View HTML- Document ID
- 16176309963865341124
- Author
- Abraham A
- Cohen A
- Shane E
- Publication year
- Publication venue
- Clinical obstetrics and gynecology
External Links
Snippet
This article will discuss the diagnosis of osteoporosis in premenopausal women and the evaluation and management of those with low-trauma fractures and/or low bone mineral density. As secondary causes (glucocorticoid excess, anorexia nervosa, premenopausal …
- 208000001132 Osteoporosis 0 title abstract description 59
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abraham et al. | Premenopausal bone health: osteoporosis in premenopausal women | |
| Langdahl | Osteoporosis in premenopausal women | |
| Jolly et al. | Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years | |
| Cohen | Premenopausal osteoporosis | |
| Suzuki et al. | Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update | |
| Drake | Osteoporosis and cancer | |
| Koetz et al. | Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy | |
| Greenspan et al. | Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial | |
| Kyvernitakis et al. | The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK | |
| Miziak et al. | The problem of osteoporosis in epileptic patients taking antiepileptic drugs | |
| McLendon et al. | A review of osteoporosis management in younger premenopausal women | |
| Hewlett et al. | Update on primary ovarian insufficiency | |
| Bachrach | Diagnosis and treatment of pediatric osteoporosis | |
| Gordon et al. | Adolescents and bone health | |
| Pinkerton et al. | Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options | |
| Meeta et al. | Clinical practice guidelines on postmenopausal osteoporosis:* An executive summary and recommendations–Update 2019–2020 | |
| Fok et al. | Update on emergency contraception | |
| Summey et al. | Glucocorticoid-induced bone loss in dermatologic patients: an update | |
| Hibler et al. | Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study | |
| Triantafyllidou et al. | Dehydroepiandrosterone (DHEA) supplementation and IVF outcome in poor responders | |
| Cohen et al. | Evaluation and management of the premenopausal woman with low BMD | |
| Naylor et al. | Long-term changes in bone mineral density in kidney transplant recipients | |
| Irwig | Male hypogonadism and skeletal health | |
| Gallagher et al. | Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials | |
| Aalberg et al. | Effect of oral and transdermal oestrogen therapy on bone mineral density in functional hypothalamic amenorrhoea: a systematic review and meta-analysis |